Pancreatic Ductal Adenocarcinoma

Oncology·MeSH: Pancreatic Neoplasms

Prevalence

7.1 / 100K

Incidence

7.5 / 100K/yr

51 drugs in development·26 companies·40 clinical trials

Drug Pipeline by Phase

Phase 3(7)

Drug	Company
[18F]FAPI-74 PET/CT	ENANTA PHARMACEUTICALS INC (ENTA)
5-FU	Tango Therapeutics, Inc. (TNGX)
batiraxcept	Aravive, Inc. (ARAV)
CAN-2409	Candel Therapeutics, Inc. (CADL)
nis793	Novartis AG (NVS)
Olaparib	Merck & Co., Inc. (MRK)
Pemetrexed	ELI LILLY & Co (LLY)

Phase 2(9)

Drug	Company
Autogene cevumeran	Tango Therapeutics, Inc. (TNGX)
Autogene cevumeran	Merus N.V. (MRUS)
BXCL701	BioXcel Therapeutics, Inc. (BTAI)
BXCL701	Merck & Co., Inc. (MRK)
cetuximab	Verastem, Inc. (VSTM)
lsta1	LISATA THERAPEUTICS, INC. (LSTA)
nuzefatide pevedotin	BICYCLE THERAPEUTICS PLC (BCYC)
OSE2101	IGM Biosciences, Inc. (IGMS)
vs-7375	Verastem, Inc. (VSTM)

Phase 1(25)

Drug	Company
[177lu]lu-nns309	Novartis AG (NVS)
[68ga]ga-nns309	Novartis AG (NVS)
[ga-68]-pnt6555	ELI LILLY & Co (LLY)
[lu-177]-pnt6555	ELI LILLY & Co (LLY)
177lu-dfc413	Novartis AG (NVS)
5-FU	Xencor Inc (XNCR)
68ga-dfc413	Novartis AG (NVS)
68ga-nns309	Novartis AG (NVS)
ASP2138	Tango Therapeutics, Inc. (TNGX)
ASP2138	Merus N.V. (MRUS)
ASP2138	Xencor Inc (XNCR)
Botensilimab	AGENUS INC (AGEN)
Emavusertib	Amneal Pharmaceuticals, Inc. (AMRX)
leucovorin	ELI LILLY & Co (LLY)
Leucovorin	Xencor Inc (XNCR)
ly3962673	ELI LILLY & Co (LLY)
ly4066434	ELI LILLY & Co (LLY)
mFOLFIRINOX	Aclaris Therapeutics, Inc. (ACRS)
mFOLFIRINOX	BioNTech SE (BNTX)
ONT01	ENANTA PHARMACEUTICALS INC (ENTA)
PTM-101	Merus N.V. (MRUS)
Quemliclustat	Arcus Biosciences, Inc. (RCUS)
Zunsemetinib	Tango Therapeutics, Inc. (TNGX)
Zunsemetinib	Merus N.V. (MRUS)
Zunsemetinib	KYNTRA BIO INC. (KYNB)

Preclinical(2)

Drug	Company
neo-stc-01	Neon Therapeutics, Inc. (NTGN)
VPS4A inhibitors (novel series)	Calithera Biosciences, Inc. (CALA)

Phase 1/Phase 2(6)

Drug	Company
[203pb]pb-psv359	Perspective Therapeutics, Inc. (CATX)
[212pb]pb-psv359	Perspective Therapeutics, Inc. (CATX)
Cetuximab	ELI LILLY & Co (LLY)
eli-002 7p	Elicio Therapeutics, Inc. (ELTX)
PSV359	Perspective Therapeutics, Inc. (CATX)
Pumitamig	BioNTech SE (BNTX)

Phase 2/Phase 3(2)

Drug	Company
folinic acid/ leucovorina	AbbVie Inc. (ABBV)
navlimetostat	BRISTOL MYERS SQUIBB CO (BMY)

BioSniper tracks 51 drugs in development for Pancreatic Ductal Adenocarcinoma across 26 companies.

There are 40 clinical trials targeting Pancreatic Ductal Adenocarcinoma tracked by BioSniper.

The estimated prevalence of Pancreatic Ductal Adenocarcinoma is approximately 7.1 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.